LISBON, Portugal, April 3, 2013 /PRNewswire/ –Hovione today announced a co-promotion and collaboration agreement with Ligand to
provide Hovione’s customers efficient access to Captisol(R) technology.
Captisol, a chemically modified cyclodextrin, is proven to improve the solubility and
stability of drugs and is currently used in six marketed products. Hovione offers
innovative particle engineering technologies to improve the solubility of modern drugs.
The agreement allows Hovione to use Captisol technology in its solubilization programs,
which include amorphous solid dispersions, crystal design and size reduction and control
of particle size. By adding this new technology, it increases the likelihood of solving
the molecule’s bioavailability challenges.
“Hovione is delighted to announce the ability to provide access to Captisol. There is
no single solution to improving bioavailability and for a customer to access diverse
options with a single supplier provides for greater probability of success and speedier
outcomes,” said Dr. Colin Minchom, Hovione’s Vice President of Particle Design.
“Hovione has manufactured Captisol for more than a decade, and we are very pleased to
expand our partnership to help customers succeed. Providing for greater access to Captisol
should efficiently enable the successful development of more poorly soluble molecules and
further increase our Captisol partnership portfolio,” said Mr. Mathew W. Foehr, Ligand’s
Executive Vice President and Chief Operating Officer.
Captisol is a patent-protected, chemically modified cyclodextrin with a structure
designed to optimize the solubility and stability of drugs. Captisol was invented and
initially developed by scientists at the University of Kansas’ Higuchi Biosciences Center
for specific use in drug development and formulation. This unique technology has enabled
six FDA-approved products, including Onyx Pharmaceuticals’ Kyprolis(TM), Baxter
International’s Nexterone(R) and Pfizer’s Vfend(R) IV. There are currently more than 30
Captisol-enabled products in development, including Lundbeck’s carbamazepine IV, The
Medicines Company’s MDCO-157 and Rib-X’s delafloxacin IV program.
Hovione is a global company with over 50 years’ experience in Active Pharmaceutical
Ingredient and Drug Product Intermediate development and compliant manufacture. With four
FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the
most demanding customers in the most regulated markets. Hovione offers integrated API,
particle design, formulation development and GMP manufacturing. In the inhalation area,
Hovione is the only independent company offering such a broad range of services.
For more information about Hovione, please visit http://www.hovione.com or contact
Marketing & Communication, Isabel Pina, +351-21-982-9362, e-mail: email@example.com.
Follow Hovione on Twitter @HovioneGroup and LinkedIn
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company that develops and acquires assets it believes
will generate royalty revenues and, under its lean corporate cost structure, produce
sustainable profitability. Ligand has a diverse asset portfolio addressing the unmet
medical needs of patients for a broad spectrum of diseases including thrombocytopenia,
multiple myeloma, diabetes, hepatitis, muscle wasting, dyslipidemia, anemia and
osteoporosis. Ligand’s Captisol platform technology is a patent-protected, chemically
modified cyclodextrin with a structure designed to optimize the solubility and stability
Please visit http://www.captisol.com for more information on Captisol or
http://www.ligand.com for more information on Ligand. Follow Ligand on Twitter
Hovione Marketing & Communication